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Abstract
Aims
The aim of this study was to assess depot-specific expression and secretion of secreted
frizzled-related protein 2 (sFRP2) by adipose tissue and its effect on adipocyte biology. We
measured serum sFRP2 concentrations in 106 patients in vivo to explore its relationship to
fat mass, glycaemia and insulin resistance.
Methods
Expression of sFRP2 in mouse and human tissues was assessed using polymerase chain
reaction and Western blot. Western blot confirmed secretion of sFRP2 by adipose tissue
into cell culture medium. Effects of recombinant sFRP2 on lipogenesis and preadipocyte
proliferation were measured. Preadipocyte expression of the angiogenic genes vascular
endothelial growth factor (VEGF) and nuclear factor of activated T-cells 3 (NFATC3)
was measured after recombinant sFRP2 exposure. Complementary clinical studies corre-
lating human serum sFRP2 with age, gender, adiposity and insulin secretion were also
performed.
Results
sFRP2 messenger RNA (mRNA) was expressed in mouse and human adipose tissue. In
humans, sFRP2 mRNA expression was 4.2-fold higher in omental than subcutaneous adi-
pose. Omental adipose tissue secreted 63% more sFRP2 protein than subcutaneous.
Treatment with recombinant sFRP2 did not impact on lipogenesis or preadipocyte prolifera-
tion but was associated with increased VEGF mRNA expression. In human subjects, circu-
lating insulin levels positively correlated with serum sFRP2, and levels were higher in
patients with abnormal glucose tolerance (34.2ng/ml) compared to controls (29.5ng/ml). A
positive correlation between sFRP2 and BMI was also observed.
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Conclusions
Circulating sFRP2 is associated with adipose tissue mass and has a potential role to drive
adipose angiogenesis through enhanced VEGF expression.
Introduction
Truncal adiposity is a risk factor for type 2 diabetes mellitus, but the nature of the relationship
between adipose tissue (AT) mass and pancreatic beta cell function is not clear. The association
between insulin resistance and fat mass suggests that changes in the adipocytokinemilieumay
have a role in the regulation of insulin secretion or a paracrine effect on adipocyte function.
TheWnt (wingless/integrated) signalling system acts by binding and activating cell surface
frizzled receptors. Wnt signalling plays an important role in morphogenesis of several organ
systems [1, 2] including prenatal pancreatic beta cell development [3] and postnatal beta cell
function and proliferation [4–6]; and in pathological diseases such as cancer [7] and cardiac
fibrosis [8]. Several studies confirmed a pivotal role of Wnt signalling in decreasing adipogen-
esis through down regulation of PPAR-gamma (peroxisome proliferator-activated receptor-
gamma) and C/EBPs (CCAAT enhancer binding proteins) expression [9–11].
Secreted frizzled-related proteins (sFRPs) form a family of secreted glycoproteins; these are
circulating soluble proteins that contain a cysteine-rich domain with homology for cell surface
frizzled receptors. sFRPs are thought to act as pre-receptor Wnt antagonists by binding circu-
latingWnt ligands. The action of individual sFRPs has been investigated in animal models:
treatment with recombinant Wnt3a protein activatedWnt signalling and increased cell expan-
sion of mouse insulinoma cell line (MIN6) [5], rat INS1 cell line [12] and primarymouse islet
cells [6], and this effect was reversed by co-treatment with sFRP1 [6]. sFRP5 is decreased in the
pancreas of obese rats and humans, and its gene silencing activates theWnt signalling pathway
and promotes beta cell proliferation [13]. A recent cross-sectional clinical study of serum
sFRP4 in humans with type 2 diabetes mellitus compared to pre-diabetes and normal glucose
tolerance subjects revealed higher sFRP4 in subjects with diabetes and a positive correlation
between sFPR4 and age, insulin levels, HbA1c and triglycerides [14]. Secreted frizzled-related
protein 2 (sFRP2) belongs to this glycoprotein family, and its mRNA was shown to be present
in human preadipocytes, rodent AT [15] and human AT [16]. The findings of cancer studies
suggest that sFRP2 acts as a Wnt agonist in certain tumour tissues [17] and that it can be a
Wnt agonist or antagonist at different tissue concentrations. In tissues with low levels of sFRP2
expression, sFRP2 appears to augment Wnt signalling and to inhibit Wnt at higher levels, as
has been reported also with sFRP1 [8, 18].
Recently, mRNA expression of 5 sFRP family members was characterised in human AT
where the sFRP2 mRNA levels in subcutaneous adipose tissues were positively correlated with
insulin resistance [16]. These previous findings suggested that sFRP2 could have effects on adi-
pose tissues. No human study has reported associations between circulating sFRP2 and glycae-
mic status nor sFRP2 in humans with a range of different bodymass indices. Therefore the
previous studies did not establish whether sFRP2 production by adipose tissue was of benefit in
glucose homeostasis nor define the effect of sFRP2 on the adipocyte.
We have performed a series of in vitro experiments using animal and human cells to assess
the depot-specific expression and secretion of sFRP2 by adipose tissue and to explore its
potential role in adipocytemetabolism, glucose and lipid homeostasis, and insulin resistance.
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Importantly, we have translated our findings into a clinical setting by examining sFRP2 levels
in the serumof 106 patients with a range of BMI and glucose tolerance.
Methods
Human Subjects
Paired fasting insulin and glucose levels were measured in 106 subjects [69 female; median
BMI 28.9 kg/m2 (range 19.0–43.9); median age 42 years (20–67)]. Fifty-three of these subjects
underwent dual energy X-ray absorptiometry (DXA) measurements of adipose tissue mass and
distribution. Sixty-five patients underwent a 2-hour oral glucose tolerance test for assessment
of glucose tolerance using the American Diabetes Association diagnostic criteria [19]. Subjects
were diagnosedwith abnormal glucose tolerance if they met criteria for impaired fasting glu-
cose, impaired glucose tolerance or diabetes mellitus based on the results of this test. All serum
samples were analysed for sFRP2 levels. All patients gave written informed consent for inclu-
sion in the study as approved by the appropriate research ethics committees. (National
Research Ethics Service references 12/WM/1206 and 04/Q2707/278; University of Birmingham
Biomaterials Ethics number 5389).
Human serum assays
Human serum sFRP2 levels were measured using a commercially-available ELISA (USCNK
Life Science Inc, B2 Scientific Limited, UK). Intrassay and interassay coefficients of variation
(CV) for this assay were< 10% and< 12% respectively. Insulin was measured using a com-
mercially-available colorimetric ELISA (Mercodia, Uppsala, Sweden) with an in-house CV
of< 5%. Glucose, triglyceride and HbA1c were analysed on a standard automated platform
(RocheModular system, Roche, Lewes, UK). Fasting glucose and insulin levels were used in the
homeostasis model assessment computer model (HOMA2-IR) to generate estimates of insulin
sensitivity. HOMA%B is considered to be a measure of pancreatic beta-cell function and is
expressed as a percentage [20].
Dual energy X-ray absorptiometry (DXA) scanning
Body composition analysis was performed using Dual-energy x ray absorptiometry (DXA)
with a total body scanner (9QDR 4500: Hologic, Bedford,MA). Coefficientsof variation for
multiple scans were 3%. Total fat (g) was calculated from the sum of arm, leg and trunk fat.
Human Adipose Tissue (AT); Primary culture; Adipose Stromal Cell
isolation
Paired primary human subcutaneous (SC) and omental (OM) adipocyteswere isolated from
adipose of healthy donors undergoing abdominal surgery for non-malignant, non-inflamma-
tory conditions, from the University of BirminghamHuman Biomaterials Resource Centre [12
males and 7 females; median bodymass index (BMI) 29.0 kg/m2, range 20.8–37.9; age 62 years
range 32–81] [21]. Briefly, adipose tissue samples were digested with 2mg/ml type 2 collagenase
at 37°C for one hour followed by sterile filtration through layered gauze to remove solid com-
ponents. After centrifugation, the stromovascular pellet containing preadipocytes was re-sus-
pended in medium and plated in 12- or 24-well plates. Adipocytes and adipose-stromal cells
(ASC) were separated by centrifugation at 100G for 5 minutes at room temperature. For exper-
iments on preadipocytes, cells were grown to confluence and exposed to treatments in serum-
free medium for 24 hours before biomaterial extraction. For testing of angiogenic gene mRNA
expression these cells were treated with recombinant sFRP2 (rsFRP2) 400ng/ml for 48 hours
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(mouse rsFRP2 with 98% homology to human sFRP2, R&D Systems, Oxford, UK). This dose
was chosen as it corresponds to a dose of 7.3nM for a 55kDa protein, which falls within the
range used in previously-published work [16]. Subsequent experiments (see de novo lipogenesis
and proliferation assay) were performed in human cell lines with concentrations that were
more representative of the physiological circulating concentrations (see Results for circulating
human concentrations). For experiments on mature adipocytes, preadipocytes were grown to
80% confluence before differentiation over 14 days in chemically-definedmedia into differenti-
ated adipocytes.
Adipose Tissue Conditioned Medium (ATCM)
To evaluate sFRP2 secretion from AT explants, 1g of paired SC and OM AT explants were
incubated in serum free Dulbecco’s Modified Eagle’s Medium (DMEM) in air/5% CO2 at 37°C
for 48 hours. AT was collected from 5 patients (2 male; BMI> 25 kg/m2). Proteins from
ATCM were concentrated using Vivaspin columns (10,000 molecular weight cut-off value; Sar-
torius UK).
Human preadipocyte cell line
The human Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell line was obtained
from Professor MartinWabitsch at the University of Ulm. Cells were differentiated into adipo-
cytes according to previously published protocols [22]. The SGBS cell line was derived from
the stromal cell fraction of SC adipose tissue from a male infant with Simpson-Golabi-Behmel
syndrome (SGBS), a rare X-linked congenital overgrowth syndrome. Proliferating SGBS cells
were seeded in 12- or 24-well plates and grown to confluence in DMEM-F12 (Sigma Aldrich,
Gillingham, UK) with 10% fetal calf serum (Life Technologies), additionally supplemented
with 33μM biotin, 17μM pantothenate and penicillin-streptomycin 1% (growth media). In pre-
adipocyte studies, cells were exposed to treatments, and biomaterial extracted, before differen-
tiation. In adipocyte studies, SGBS cells were differentiated over 14 days in chemically defined
medium. All cells were cultured in serum-mediumfor 24 hours before experiments.
RNA extraction and Reverse Transcription
Total RNA was extracted from AT, adipocytes and ASC using TriReagent (Sigma-Aldrich,
UK) according to the manufacturer’s protocol. RNA concentration was measured using a
NanoDrop-1000 spectrophotometer (Agilent, UK) and integrity of RNA confirmed on 1%
agarose gel. 500ng of total RNA was reverse transcribed using a High Capacity Reverse Tran-
scription Kit (Applied Biosystems, UK) in 20 μl RT reaction as described in manufacturer’s
protocol. cDNA was diluted to 10ng/ μl for PCR reactions.
Conventional sFRP2 PCR
PCR reactions were carried out in 20μl volume using 40ng of cDNA, 10ng of each primer, at
60°C annealing temperature for 32 cycles. PCR products were separated on 1% agarose gel
with 1:20,000 GelRed (Biotium, UK) and visualised using GeneSnap software (Syngene UK).
All reagents were purchased from Promega (UK) unless specified otherwise.
Human sFRP2 primers sequence (345bp): forward: CTGCCACCGCTTCACCGAGG, reverse:
CCAGCCACCGAGGAAGCTCCA.
Mouse sFRP2 primers sequence (320bp): forward: ACGACAACGACATCATGGAA, reverse:
GGAGATGCGCTTGAACTCTC.
SFRP2 and Human Metabolic Disease
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Real time PCR (qPCR)
qPCR reactions were carried out in 20μl volume in 96-well plates with equal amount of cDNA
(10ng) using ABI Prism 7500 SequenceDetection System (PE Applied Biosystems, UK).
Housekeeping gene, 18S rRNA was used for relative gene expression. This enabled data to be
expressed in relation to an internal reference to allow for differences in RT efficiency. Measure-
ments were carried out at least three times for each sample. Primers and probe for all genes,
including 18S rRNA as endogenous control, were purchased as the pre-made Expression
Assays (Applied Biosystems, UK). According to the manufacturer’s guidelines, data were
expressed as Ct values (the cycle number at which logarithmic PCR plots cross a calculated
threshold line) and used to determineΔCt values (ΔCt = Ct of the target gene minus Ct of the
housekeeping gene). Relative gene expression data were calculated and presented as a fold
increase over control. All statistics were performed on ΔCt values.
Western blots on secreted sFRP2 protein from AT explants
Concentrated proteins from adipose tissue conditionedmedium (ATCM) were separated on
10% acrylamide gel and immobilised to polyvinylidenemembrane using semi-dry blot (Invi-
trogen, UK). They were immunoblotted overnight at 4°C with rabbit polyclonal sFRP2 anti-
body at 1:100 dilution (Milliprore, UK). Blots were incubated for 1 hour at room temperature
with anti-rabbit secondary antibody at 1:20,000 dilution and specific bands visualised using
Luminata CrescendoWestern HRP Substrate (Millipore, UK).Western blot band intensity was
measured using GeneSnap software (SynGene, Cambridge, UK).
Mouse tissues
C57BL/6 mice aged 6–8 weeks (Jackson Laboratories,ME, USA) were housed in accordance
with animal care protocols at the University of Birmingham, UK. Mice were maintained on a
12:12h light-dark schedule at 22°C, with up to 4 mice per cage. Mice were killed by cervical dis-
location under terminal general anaesthesia using isofluorane prior to organ retrieval.Mouse
gonadal fat (GF; equivalent of human OM tissue), pancreas and liver were collected in accor-
dance with approved UKHome Office licences. Total RNA was extracted by homogenising tis-
sues in TriReagent (Sigma-Aldrich,UK).
De novo lipogenesis
Lipogenesis was measured by the uptake of 1-[14C] acetate into the lipid component of adipo-
cytes [23]. After differentiation for 14 days, SGBS cells were washed and cultured in serum-free
medium for 4 hours. Cells were then treated, with and without sFRP2 (50ng/ml and 100ng/
ml), in serum-freemedium for 18 hours. Hot (1-[14C]) and cold sodium acetate were then
added to treatment wells for a further 6 hours. Cells were then washed three times and scraped
with 250μl cold phosphate-buffered saline; cell lysate was transferred to glass thin layer chro-
matography capillary spotter tubes. Folch solvent (chloroform:methanol 2:1) 5ml was added to
each tube to recover the lipid fraction; samples were mixed vigorously, followed by the addition
of 1ml distilledwater to each tube. Samples were separated into two phases after centrifugation
at 12,000 for 5 minutes—aqueous (upper) and solvent (lower), with protein interface. The sol-
vent fractionwas recovered and transferred to scintillation tubes followed by evaporation to
dryness overnight. Liquid scintillation cocktail (4ml, Fisher Scientific, Loughborough,UK) was
added to each vial. Radioactivity retained in the cellular lipid was determined by scintillation
counting and expressed as disintegrations per minute (DPM)/per well. Due to inter-assay vari-
ability, results were expressed as % change from controls per well.
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Proliferation study
SGBS preadipocytes were seeded into a 96-well plate. Following overnight culture cells were
treated with 100ng/ml sFRP2 and compared to untreated controls. At Day 1, 3, 6, 8 and 10 cell
proliferation was assessed using a nonradioactive cell proliferation assay (Promega, Madison
WI) according to the manufacturer’s protocol. Luminescencewas recorded at 490nm utilising
a plate reader (Victor Wallac 3, Perkin Elmer). Results from controls were compared to
sFRP2-treated cells using analysis of variance (ANOVA).
Statistics
Statistical analysis was performed using IBM SPSS Statistics (IBM, Armonk, NY). Data were
tested for normality using the Shapiro-Wilk test. Normally-distributed data were described
using either mean and standard deviation (SD, clinical data), and mean and standard error of
the mean (SEM, in vitro data), and compared using t-tests; data that were not normally distrib-
uted were describedusing median and range and compared using the MannWhitney test. Cor-
relation analysis was performed using Spearman’s rho test. Multiple linear regression was
performed to confirm the relationship between clinical variables and sFRP2. ANOVA was used
for analysis of the effect of sFRP2 on proliferation.
P values of 0.05 or less were considered statistically significant.
Results
Tissue-specific expression of sFRP2 in mouse and human tissues
RT-PCR onmouse tissues and cell lines revealed sFRP2mRNA expression inmouse GF and SC
fats but not in liver, pancreas and mouse pancreatic beta and alpha cell lines,MIN6 and TC1.9
respectively, Fig 1A. SFRP2mRNA expression was detected in human pancreas, SC and OMAT
but not in liver or isolated hepatocytes, Fig 1B. After digestion of human AT to isolate adipocytes
and ASC, RT-PCR showed sFRP2mRNA expression in human SC and OM adipocytes, Fig 1C,
and ASC, Fig 1D. PCR for 32 cycles was indicative of higher expression in OM depots than SCAT.
Depot-specific expression of sFRP2 in human adipose tissue
The conventional PCR findings in human AT, adipocytes and ASC were confirmed by real
time PCR. In intact human AT, sFRP2 mRNA expression was significantly higher in paired
OM than SC depots (fold change 4.2 ± 1.6, p = 0.03, n = 4, Fig 2A). sFRP2 mRNA expression
was also significantly higher in cells isolated and differentiated from OM compared to the SC
depot (fold change, 5.3 ± 1.7, p = 0.02, n = 4, Fig 2B).
Similarly, in isolated ASC, OM ASC sFRP2mRNA expression was significantly higher com-
pared to corresponding SC expression (fold change 3.7 ± 1.0, p = 0.04, n = 4, Fig 2C). There
was no significant difference in sFRP2 mRNA expression between adipocytes and ASC from
the same AT depot, n = 8 (data not shown).
Western blot analysis for sFRP2 protein expression secreted into cell culture media revealed
that OM AT explants secreted 63%more sFRP2 than SC explants during 48 hour culture (fold
change 1.63±0.16, p<0.01, n = 5), Fig 2D.
The effect of sFRP2 on proliferation, expression of angiogenesis-
associated genes and on de novo lipogenesis
Treatment of SGBS cells with sFRP2 did not have any impact on proliferation compared to
control SGBS cells (p = 0.6). Forty-eight hour treatment of primary SC human preadipocytes
SFRP2 and Human Metabolic Disease
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with sFRP2 led to increased expression of the angiogenic gene VEGFalpha (fold change
2.3 ± 0.5, p = 0.02, n = 5, Fig 3A). The observed increase in SC preadipocytemRNA expression
of NFATC3 after treatment with sFRP2 did not reach statistical significance (fold change
1.7 ± 0.2, p = 0.07, n = 5, Fig 3B). No effects on VEGFalpha or NFATC3 mRNA expression
were observed in OM preadipocytes treated with sFRP2 (p = 0.22 and p = 0.37, respectively,
n = 5, data not shown).
There was no effect of treatment with sFRP2 on de novo lipogenesis in differentiated SGBS
cells [100% (control) v 90% ±24.8 (sFRP2 50ng/ml), p = 0.5; v 104% ±20.1 (sFRP2 100ng/ml),
p = 0.7, Fig 3C].
The relationship between sFRP2 and circulating insulin in human serum
samples
In human serum samples, sFRP2 levels were positively correlated with increased age (r = 0.29,
p<0.0002), BMI (r = 0.36, p< 0.0001) and triglycerides (r = 0.1, p = 0.01) but not HbA1c
(p = 0.5). In the subset of subjects who underwentDXA scan measurement of fat depots,
serum sFRP2 levels correlated with total fat (r = 0.10, p = 0.02); but not trunk fat (p> 0.05),
Fig 1. sFRP2 mRNA expression in mouse tissues: (A) liver, pancreas, SC AT, GF and beta and alpha pancreatic cell
lines, (B) human tissues: liver, pancreas, SC and OM AT and isolated hepatocytes, (C) isolated adipocytes from
human AT and (D) ASC cells isolated from human AT. PCR for 32 cycles. 18S PCR amplification was carried out for 20
cycles as control (data not shown).
doi:10.1371/journal.pone.0163777.g001
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Fig 4. Female subjects were found to have higher serum levels of sFRP2 than males (median
28.0, 0–43.5 ng/ml compared to 20.4, 0–42.0 ng/ml, p = 0.01).
Serum insulin (r = 0.16, p< 0.0001), HOMA%B (r = 0.12, p< 0.001) and HOMAIR
(r = 0.15, p< 0.0001) correlated with sFRP2 levels in the human subjects, Fig 5A and 5B. In a
multiple linear regression analysis of factors contributing to insulin secretion that included age
and gender, only BMI (p<0.001) and sFRP2 (p<0.05) correlated significantly with circulating
insulin concentration.
Fig 2. Relative sFRP2 mRNA expression by qPCR in (A) intact human SC and OM AT, (B) in isolated and differentiated human
adipocytes and in (C) adipose stromal cells (ASCs). (D) Western immunoblot of sFRP2 shows band intensity (area) from adipose tissue
conditioned media (ATCM) from 5 paired SC and OM explants after 48h incubation. An insert is a representative Western blot from 2
paired samples. ATCM was obtained by incubating the same amount of AT in 5ml media volume, n = 5 (D). *<0.05, **<0.01, ***<0.001.
doi:10.1371/journal.pone.0163777.g002
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Fig 3. Angiogenic gene mRNA expression (A, VEGFalpha, B, NFATC3) in primary SC human
preadipocytes treated with 400ng/ml sFRP2 for 48 hours. VEGFalpha mRNA expression was
significantly increased by sFRP2 treatment. No effects were observed in OM preadipocytes (data not
shown). Treatment with sFRP2 50ng/ml or 100ng/ml did not significantly increase de novo lipogenesis in
differentiated SGBS cells (p = 0.5 and 0.7, respectively (C).
doi:10.1371/journal.pone.0163777.g003
SFRP2 and Human Metabolic Disease
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Fig 4. Correlation between (A) serum sFRP2 (ng/ml) with age (years) r = 0.29, p<0.0002; (B) BMI (kg/m2) r = 0.36, p < 0.0001;
n = 106 (69 female); (C) total fat (g) r = 0.10, p = 0.02; and (D) trunk fat (g) r = 0.07, p > 0.05; n = 53.
doi:10.1371/journal.pone.0163777.g004
Fig 5. Correlation between (A) sFRP2 (ng/ml) and insulin (pmol/l), r = 0.16, p < 0.0001; (B) sFRP2 (ng/ml) and HOMA%B r = 0.12,
p < 0.001; n = 106; (C) sFRP2 (ng/ml) and glucose tolerance status (abnormal vs normal glucose tolerance (AGT). Abnormal
tolerance status comprises subjects with either pre-diabetes or diabetes on oral glucose tolerance test by ADA criteria), n = 65, mean
+/-SEM.
doi:10.1371/journal.pone.0163777.g005
SFRP2 and Human Metabolic Disease
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Because of the small numbers of subjects with diabetes (n = 8), these were combined with
those diagnosedwith pre-diabetes (n = 26) to create a category of abnormal glucose tolerance
(AGT; n = 34). There was a significant difference between sFRP2 levels in those with normal
(n = 31) (29.5; 16.9–43.1 ng/ml) compared to patients with abnormal glucose tolerance (34.2;
13.9–43.8 ng/ml, p< 0.01), Fig 5C.
Discussion
We have characterised the adipose tissue depot-specific expression and secretion of sFRP2.We
did not demonstrate an impact of recombinant sFRP2 on de novo lipogenesis nor on prolifera-
tion over a period of 10 days. Addition of recombinant sFRP2 to SC pre-adipocytes increased
expression of VEGF which implies that in vivo sFRP2 may have a role in increasing blood sup-
ply to and expansion of adipose tissue volume. Unlike previous studies from a clinical setting
[16], we measured circulating sFRP2 levels in serum from humans across a range of BMI and
with normal and abnormal glucose tolerance and showed a positive correlation with serum
insulin, triglyceride,HOMA%B and HOMAIR. Circulating sFRP2 was higher in female
patients and in those with abnormal glucose tolerance and correlated with increased age and
BMI. In a model of factors contributing to circulating insulin concentration, sFRP2 and BMI
were the only variables which contributed significantly to the model.
In mouse tissues as well as in human, we identified expression of sFRP2 in adipose tissue,
but not pancreas or liver. An earlier study identified sFRP2 by Northern blot in human pan-
creas using Clontech mRNA blots [15], but we were unable to detect its expression in mouse
pancreas in agreement with a human study [24] detecting sFRP2 at very low level by RT-PCR.
This suggests that any action of sFRP2 on the beta cell would be as an adipokine rather than
any autocrine effect within the pancreas. Within adipose tissue, we hypothesised that sFRP2
might act as a paracrine / autocrine agent to stimulate de novo lipogenesis or proliferation of
preadipocytes; this was not demonstrated. However, we observed an increase in VEGF gene
expression suggesting a potential impact on angiogenesis. It is plausible therefore that total
body fat might gradually increase over time in response to sFRP2-stimulated angiogenesis and
increased blood flow to adipose tissue depots.
It was a limitation of the studies that the in vitro model was with cellular rather than tissue
material, and thus an effect of increased angiogenesis within adipose tissue could not be evalu-
ated. Another limitation of our study is that we did not assess Wnt pathway activation by
sFRP2, to establish whether its action at the concentrations studied is that of an agonist or
antagonist. However, the findings in our clinical study endorse the tight relationship between
sFRP2, adipocyte biology and markers of insulin secretion and pancreatic beta cell function.
Human visceral obesity is strongly associated with cardiovascular risk [25, 26]. Our clinical
study has shown a positive association between serum sFRP2, BMI and total fat; thus it is possi-
ble that sFRP2 from the visceral adipose depot might contribute to hyperinsulinaemia and car-
diovascular risk. In animal models of heart failure, sFRP2 expression was increased, and
blockade of sFRP2 using an antibody resulted in improved left ventricular ejection fraction [8].
The association of sFRP2 with cardiac fibrosis and with malignant neoplasms represents a
potential common aetiology for the association of insulin resistance and diabetes with heart
failure and with cancer.
Adipose tissue expression of sFRP2 has been associated with insulin resistance [16], and this
study defined serum sFRP2 as an adipokine strongly associated with abnormal glucose toler-
ance and increased insulin secretion.Human obesity is often associated with insulin resistance,
hyperinsulinaemia and beta cell dysfunction [27]; however the mechanisms are still not
completely understood. Previous reports of sFRP2 stimulation of angiogenesis by the
SFRP2 and Human Metabolic Disease
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calcineurin pathway and inhibition of angiogenesis with antibody to sFRP2 [17] provide a clue
to the link between adipose, insulin secretion and sFRP2; the calcineurin inhibitor tacrolimus
inhibits sFRP2-inducedVEGF expression and endothelial tube formation, reduces GLUT4
expression in adipocytes to render the adipocyte insulin resistant [28] and reduces beta cell
mass [29]. It can be difficult to separate peripheral insulin resistance from compensatory
hyperinsulinaemia in order to maintain euglycaemia—in this human study it should be noted
that the overall cohort studied had normal insulin sensitivity with a median HOMAIR of 0.8
(0.1–4.7). It is possible that sFRP2-mediated adipose tissue expansion and insulin secretion is a
potential compensatory mechanism in the setting of visceral adiposity and insulin resistance.
In conclusion, we have demonstrated differential adipose tissue specific expression of
sFRP2 and have highlighted a potential role to drive adipose angiogenesis through enhanced
VEGF expression that might explain our observed association between fat mass and circulating
sFRP2 levels. Further studies are clearly warranted to determine, in vivo, the impact of sFRP2
manipulation on fat mass and adipose tissue biology, but it could represent a novel therapeutic
target.
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